Effect of repeated vincristine administration on platelet count in cats with lymphoma.

Repeated vincristine administration does not induce thrombocytopenia in cats with lymphoma.

Vincristine is a chemotherapy agent commonly used to treat hematopoietic tumors like lymphoma in cats. While its effects on platelet counts in dogs are well-documented, information regarding its impact in cats has been limited. This retrospective cohort study aimed to assess the variation in platelet counts following repeated vincristine administrations in cats diagnosed with lymphoma. The study included 52 cats that received a total of 94 vincristine treatments, with each cat undergoing up to four sequential treatments. Platelet counts were measured before and after each vincristine administration. The results indicated that post-treatment platelet counts were consistently higher than pre-treatment counts. However, the difference became statistically significant only after the second vincristine administration, with a mean increase of 53.2 ± 124.4 × 10³/µL (p = 0.019). These findings suggest that repeated vincristine administration does not induce thrombocytopenia in cats with lymphoma and is not contraindicated in thrombocytopenic cats. The study's limitations include its retrospective design, non-standardized blood sampling protocols, and varying timings of complete blood count analyses, which may have influenced the results. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39887713/?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.